Searched for
SUN PHARMA Q3 EARNINGS UPDATE
Earnings of OMCs seen weak as Q1FY27 under-recoveries bite: ReportOil companies are projected to experience ongoing challenges through FY27, primarily due to anticipated under-recoveries in Q1FY27, with LP...- Middle East outages to keep aluminium market tight near-term, but Indonesia-China supply wave caps upside: Goldman SachsAluminium prices are expected to remain high in the short term due to ongoing Middle East disruptions, which are now projected to extend in...
- Sun Pharma adds Innovcare to its fold in Rs 271.2 crore all-cash transactionIndia's largest drugmaker, Sun Pharma, is set to acquire Mumbai-based Innovcare Lifesciences for approximately $28.7 million in an all-cash...
- Earth’s North Pole has moved 1,400 miles. What happens next has experts paying attentionEarth’s magnetic north pole has been quietly on the move for decades, traveling thousands of miles from its original position in Canada tow...
- RIL AGM: Reliance Industries shares fall 2% amid Mukesh Ambani's big announcements at 49th AGMReliance Industries shares dipped nearly 2% despite Chairman Mukesh Ambani announcing the approved Jio DRHP for a $4 billion IPO. The compa...
- Has Form 168 replaced Form 26AS for FY 25-26? Here's what taxpayers need to know for ITR filingForm 168: The Income Tax Department has unveiled Form 168, a comprehensive upgrade to the Annual Information Statement, effectively superse...
- Accenture signals caution, but analysts see long-term IT opportunityAccenture's earnings signal tough times for IT services. Indian IT firms face weak demand and cautious client spending. While valuations ar...
- ICICI Prudential AMC shares fall 2% as IPO lock-in expiry frees up Rs 1.2 lakh crore stake for tradeICICI Prudential AMC shares dropped 2% to Rs 513 as 34.4 crore shares became eligible for trade post IPO lock-in expiry. The company's stoc...
- TCS, Infosys, Wipro, other IT stocks crash up to 8% as Accenture lowers FY26 guidanceIndian IT stocks, including TCS and Infosys, tumbled up to 8% after Accenture lowered its annual revenue growth forecast, signaling continu...
- Reality Check: What triggered Accenture's historic stock plungeAccenture's biggest-ever stock plunge was driven by weaker revenue guidance, slowing bookings and rising investor concerns that AI-led disr...
- ETMarkets PMS Talk | Dinshaw Irani of Helios India stays away from IT, doubles down on domestic consumption amid AI disruptionHelios India is steering clear of IT stocks, citing AI's disruptive potential, and instead champions India's domestic consumption. The firm...
- Aashaan OTT release date details: Where and when to watch the Malayalam comedy-drama directed by Johnpaul GeorgeThe Malayalam comedy-drama Aashaan, directed by Johnpaul George and starring Indrans in the lead role, is set to make its OTT debut soon. T...
- Christy Mathai used market dip to buy insurance, logistics stocks; here's his sector-by-sector playbookFund Manager Christy Mathai sees easing war-driven inflation fears, expecting a shorter earnings hit. He's selectively adding to his portfo...
- Buy, Sell or Hold: Goldman Sachs remains neutral on Tata Motors; Nuvama maintains buy on HULBrokerages show selective optimism amidst market jitters. Goldman Sachs backs Shyam Metalics & Energy with a 10% upside target, anticipatin...
- EPFO 3.0 features: Check auto-claim limits, UPI withdrawals and member checklist
- The 30% smallcap tilt: How Abakkus Flexi Cap Fund is positioning for the next rallyAbakkus Mutual Fund is strategically allocating 30% to smallcaps within its Flexi Cap Fund, identifying mispriced opportunities despite str...
- Sweet pills: How pharma stocks delivered bumper returns to Indian investors, defying 2026 whiplashIndian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...
- Betting big on mid and smallcaps; largecaps most expensive on PEG basis, says Dinshaw IraniHelios Mutual Fund is shifting investments from large companies to mid and small companies. This move follows earnings growth trends where ...
- Promoter sells Rs 1,024 crore worth of Ajanta Pharma shares in block deal to Kotak MF and ABSL MFA promoter entity of Ajanta Pharma sold shares worth over Rs 1,024 crore through a block deal, with Kotak Mahindra Mutual Fund and Aditya B...
- SBI in $1 billion funding for Sun Pharma’s US dealState Bank of India is set to commit up to $1 billion to fund Sun Pharmaceutical Industries Ltd.'s $12 billion acquisition of Organon & Co....
Load More
